Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (3352)	6/25/1999 12:38:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

There is a huge expressed SEPR institutional buyer interest overhang of about 650K shares right now, and not even one seller interest all day. This is equal to a full days volume almost. They seem to be cautiously low priced expressions. Is this preparation for the end of the second quarter? Have we been experiencing an end of quarter positioning phase? This much buy expression looks real good to me. thomsoninvest.net.

To: quidditch who wrote (3352)	6/25/1999 3:01:00 PM
From: BDR	Respond to of 10280

If Medicare coverage is extended to drugs the first thing that will happen is that the feds will demand discounts in price to at least match that given to HMOs and others buying in bulk. With the cost to beneficiaries removed as a deterrent to prescription use, demand will increase. That's no great insight, just basic economics. Facing the inevitable increase in expenses the feds will either 1)demand further price cuts, 2)raise Medicare taxes further to pay for the increase, 3) restrict access (require generics, resort to formularies, cap expenditures etc.). There are significant constituencies that will oppose 2 and 3. The only ones that would oppose #1 are the drug companies and their shareholders and I don't see them getting much sympathy on Capitol Hill.